Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal Inflammatory Profiles Associated With Perinatally Acquired Hepatitis C Viral Infection.

The Pediatric infectious disease journal·2026
Same author

Atherosclerotic cardiovascular disease (ASCVD) biomarkers 5-10 years after a hypertensive disorder of pregnancy.

Pregnancy hypertension·2026
Same author

Maternal cytomegalovirus serology results by geographic region in a large multicenter United States study.

The Journal of infectious diseases·2026
Same author

Maternal Depression and Opioid Use After Cesarean Delivery.

Obstetrics and gynecology·2026
Same author

Childhood sexual abuse and post-cesarean pain.

Pregnancy (Hoboken, N.J.)·2026
Same author

Pulse Pressure and Adverse Maternal and Perinatal Outcomes in Patients With Mild Chronic Hypertension During Pregnancy.

O&G open·2025
Same journal

Obstetric Care for Patients With Cognitive Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Dissecting the Americans With Disabilities Act (ADA) Requirements when Approaching Obstetric Patients With Disabilities: How to Ensure Your Spaces are Accessible for All.

Clinical obstetrics and gynecology·2026
Same journal

Clinician Comfort and Barriers to the Obstetric and Gynecologic Care of Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Obstetric Care for Patients With Visual Impairments: Preconception Counseling Through Postpartum Care.

Clinical obstetrics and gynecology·2026
Same journal

Menstrual Management and Contraception for Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Favoring Elective Hospitalization in Pregnancies With Vasa Previa.

Clinical obstetrics and gynecology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Subclinical thyroid dysfunction during pregnancy.

Brian M Casey1

  • 1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. brian.casey@utsouthwestern.edu

Clinical Obstetrics and Gynecology
|August 23, 2011
PubMed
Summary
This summary is machine-generated.

Screening pregnant women for subclinical thyroid dysfunction is being considered, but evidence for routine screening and treatment is currently lacking. Further trials are needed before widespread implementation.

More Related Videos

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

Related Experiment Videos

Last Updated: May 30, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

Area of Science:

  • Obstetrics and Gynecology
  • Endocrinology
  • Clinical Trials

Background:

  • Subclinical thyroid dysfunction in pregnancy is a growing concern.
  • There is a strong rationale for identifying affected pregnant individuals.
  • Current evidence supporting universal screening and treatment is insufficient.

Purpose of the Study:

  • To evaluate the need for routine screening of pregnant women for subclinical thyroid dysfunction.
  • To assess the current evidence base for intervention strategies.
  • To inform clinical practice guidelines regarding thyroid function testing in pregnancy.

Main Methods:

  • Review of existing data and clinical rationale for screening.
  • Assessment of the current evidence for treatment efficacy.
  • Anticipation of results from ongoing and peer-reviewed clinical trials.

Main Results:

  • Compelling data exists to warrant screening for subclinical thyroid dysfunction in pregnant women.
  • Robust evidence to support routine screening and subsequent treatment is currently lacking.
  • Key clinical trials are in progress or under review.

Conclusions:

  • Routine screening and treatment for subclinical thyroid dysfunction in pregnancy is premature at this time.
  • Clinical practice should await further evidence from ongoing research.
  • Future trials are expected to clarify the role of screening and treatment.